METHOD FOR FORMING AN EXPERIMENTAL MODEL OF A COMBINATION OF TYPE 1 DIABETES MELLITUS AND ENDOMETRIOSIS Russian patent published in 2022 - IPC G09B23/28 A61B17/00 A61P29/00 A61P31/04 A61P5/30 A61K31/565 A61K9/08 A61P3/10 A61P5/48 A61K38/28 A61B5/157 G01N33/66 

FIELD: medicine.

SUBSTANCE: invention relates to experimental medicine, namely surgery, endocrinology. Modeling of endometriosis in rats is performed by bilateral ovariectomy, followed by removal of the left uterine horn at the bifurcation site and the formation of fragments of endometrioid tissue measuring 3×3 mm. The formed tissue fragments are implanted on the outer surface of the anterior abdominal wall under the skin. Within 4 weeks after surgery, an oil solution of ethinyl estradiol, 50 mcg/kg is injected intramuscularly twice a week. 2 weeks after the surgical intervention, 0.9% alloxan saline solution at a dosage of 150 mg/kg is administered intraperitoneally to animals in which a model of endometriosis was formed during visual control. At the same time, during the first 48 hours after the introduction of alloxan, glycemia is monitored 2 times a day with constant access of animals to water and a solution of 30% glucose. An increase in the level of glycemia above 11 mmol/l and the level of ketone bodies in the blood above 1.5 mmol/l on day 2-5 is a confirmation of the formation of type 1 diabetes mellitus. After that, long-acting insulin-glargine is injected subcutaneously daily for 2 weeks 1-2 times a day, and at a glycemic level of 11-19 mmol/l - 1 unit, 20-29 mmol/l - 2 units, 30-33 mmol/l - 3 units, above 33 mmol/l - once, short-acting insulin aspart - 1 unit.

EFFECT: method makes it possible to study the features of the course of the combination of endometriosis and type 1 diabetes mellitus, their mutual influence, to identify the limitations and possibilities of both existing therapy and that being developed in order to improve treatment results.

1 cl, 1 dwg, 1 ex